Natural Killer Cell

A natural killer (NK) cell is a large granular cytotoxic lymphocyte belonging to Group 1 of the innate lymphoid cell (ILC) family that provides rapid frontline surveillance against intracellular viruses and malignantly transformed cancer cells without requiring prior clonal sensitization or somatic V(D)J receptor gene rearrangement. Comprising 5% to 15% of circulating peripheral blood lymphocytes in humans (and resident populations in the spleen, liver, lungs, bone marrow, and gravid uterine decidua), NK cells were first identified in 1975 by Rolf Kiessling, Ronald Herberman, and colleagues on the basis of their intrinsic "natural" cytotoxicity against murine lymphoma target lines in the absence of prior immunization.

Developing from common lymphoid progenitors (CLPs) in the bone marrow and secondary lymphoid tissues under the control of the transcription factors EOMES (Eomesodermin), T-bet (TBX21), and ID2 and the survival cytokine interleukin-15 (IL-15), human NK cells are phenotypically defined as CD56⁺CD3⁻NKp46⁺ lymphocytes (lacking T-cell receptors [CD3/TCR] and B-cell immunoglobulins [CD19]). Whereas cytotoxic CD8⁺ T cells detect foreign antigenic peptides presented on self-Major Histocompatibility Complex (MHC) Class I molecules, NK cells operate on a complementary evolutionary logic formulated by Klas Kärre in 1985 as the "missing-self" hypothesis: they spare healthy host cells that display intact self-MHC Class I molecules while selectively lysing target cells that have downregulated MHC Class I to evade T-cell detection or upregulated cellular stress ligands ("induced-self").

CD56-Bright vs. CD56-Dim Functional Dichotomy

In humans, mature NK cells are partitioned into two major developmental and functional subsets based on surface expression density of the neural cell adhesion molecule isoform CD56 (NCAM1) and the low-affinity Fcγ receptor CD16 (FcγRIIIA):

• CD56^brightCD16^dim/− Subset (~10% of peripheral blood NK cells, >75% of lymph node and tonsillar NK cells): Representing an earlier maturation stage that expresses high-affinity heterotrimeric IL-2 receptors (CD25/CD122/CD132), CCR7, and CD62L (L-selectin), CD56^bright cells contain lower levels of intracellular perforin and granzyme B and exhibit weak baseline cytotoxicity, but serve as potent immunoregulatory cytokine producers—secreting abundant interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and GM-CSF upon stimulation with dendritic-cell-derived IL-12, IL-15, and IL-18.
• CD56^dimCD16^bright Subset (~90% of peripheral blood and splenic NK cells): Differentiating from CD56^bright precursors, CD56^dim cells pack their cytoplasm with preformed lytic granules rich in perforin and granzyme B and express high levels of CD16 (FcγRIIIA) and killer-cell immunoglobulin-like receptors (KIRs), executing immediate serial contact-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC).

"Missing-Self" Inhibitory Receptors vs. "Induced-Self" Activating Receptors

Because NK cells lack RAG1/RAG2 recombinase-generated antigen receptors, each NK cell expresses a stochastic, variegated combinatorial array of germline-encoded inhibitory and activating receptors. Whether an NK cell kills or spares an encountered cell is governed by a quantitative tug-of-war integrated at the immunological synapse:

1. Inhibitory Receptors (Sensing "Self" MHC Class I): Healthy nucleated vertebrate cells constitutively express classical polymorphic MHC Class I molecules (HLA-A, HLA-B, and HLA-C in humans; H-2K, D, L in mice) and non-classical HLA-E. NK cells survey these molecules via two main structural families:

• Killer-Cell Immunoglobulin-Like Receptors (KIRs, encoded on human chromosome 19q13.4): Monomeric type I transmembrane glycoproteins possessing two or three extracellular Ig-like domains (KIR2DL / KIR3DL) that recognize specific allotypic epitopes on HLA-C (group C1 Asn80 vs. group C2 Lys80) or HLA-B (Bw4) and HLA-A. (Rodents use a convergent C-type lectin family called Ly49 to perform the exact same MHC-I-sensing role.)
• CD94/NKG2A Heterodimers: Conserved C-type lectin-like heterodimers that recognize the non-classical MHC-Ib molecule HLA-E (Qa-1^b in mice) loaded with leader signal peptides derived from classical HLA-A, -B, and -C molecules—providing a global readout of overall cellular MHC-I biosynthesis.

All inhibitory NK receptors carry one or more conserved Immunoreceptor Tyrosine-Based Inhibitory Motifs (ITIMs, consensus sequence I/V/L/S-X-Y-X-X-L/V) in their cytoplasmic tails. Upon engaging self-MHC Class I on a healthy cell, the ITIM tyrosine is phosphorylated and recruits the Src-homology 2 (SH2) domain-containing protein tyrosine phosphatases SHP-1 and SHP-2 (and lipid phosphatase SHIP-1), which dephosphorylate Vav1, LAT, and SLP-76 to abort actin polymerization and lytic granule exocytosis upstream of irreversible commitment.

1. Activating Receptors (Sensing "Induced-Self" Stress Ligands and IgG): When a cell suffers DNA damage, oncogenic transformation, or viral infection, it upregulates stress proteins that engage NK activating receptors:

• NKG2D: A homodimeric C-type lectin receptor (coupled to the DAP10 signaling adaptor via a YINM motif that recruits PI3K and Grb2) that recognizes MHC-Class-I-related stress ligands MICA, MICB, and ULBP1–6, which are absent on healthy cells but transcriptionally induced by the ATM/ATR DNA damage response and heat shock.
• Natural Cytotoxicity Receptors (NCRs — NKp46, NKp44, and NKp30): Immunoglobulin-superfamily receptors coupled to ITAM (Immunoreceptor Tyrosine-Based Activation Motif, Y-X-X-L/I-X_6–8-Y-X-X-L/I)-bearing adaptors (CD3ζ, FcεRIγ, or DAP12) that bind viral hemagglutinins, B7-H6 tumor ligands, and PDGF-DD.
• CD16 (FcγRIIIA): Binds the Fc region of IgG1 and IgG3 antibodies opsonizing a target cell, triggering Antibody-Dependent Cellular Cytotoxicity (ADCC) via CD3ζ/FcεRIγ ITAM phosphorylation by Src-family kinases (Lck/Fyn) and Syk/ZAP-70 activation—a mechanism critical to the clinical efficacy of therapeutic monoclonal antibodies such as rituximab (anti-CD20), trastuzumab (anti-HER2), and cetuximab (anti-EGFR).

Self-Tolerance via NK Cell Education (Licensing / Arming)

Because KIR genes (on chromosome 19) and HLA genes (on chromosome 6) segregate independently, a fraction of developing NK cells in any individual fails to express an inhibitory KIR or NKG2A receptor that recognizes the host's own HLA Class I alleles. Rather than causing autoimmunity, these receptor-negative NK cells are rendered functionally hyporesponsive (anergic) through a developmental calibration process discovered by Wayne Yokoyama and Klas Kärre termed NK cell licensing (education or arming): only developing NK cells whose inhibitory ITIM receptors productively engage self-MHC Class I molecules acquire full effector responsiveness and lysosomal secretory competence upon subsequent activating receptor stimulation.

The Lytic Immunological Synapse: Perforin, Granzymes, and Death Receptors

When activating signals override inhibitory signals (for example, on a herpesvirus-infected cell or MHC-I-deficient tumor cell expressing MICA/B), the NK cell assembles a radially symmetric lytic immunological synapse stabilized by the β₂ integrin LFA-1 (CD11a/CD18) binding ICAM-1 on the target cell. The microtubule-organizing center (MTOC) polarizes toward the synapse, directing secretory lysosomes (lytic granules) through a clearance ring in the cortical F-actin meshwork to fuse with the presynaptic membrane via Rab27a, Munc13-4 (mutated in familial hemophagocytic lymphohistiocytosis type 3), and Syntaxin-11. NK cells execute target cell apoptosis through two complementary pathways:

1. The Perforin / Granzyme Exocytosis Pathway (Rapid, <30–60 minutes): Degranulation releases two key proteins buffered silently inside acidic granules by the chondroitin sulfate proteoglycan serglycin:

• Perforin (PRF1, ~67 kDa): A monomeric MACPF/CDC-domain pore-forming protein that binds target cell membrane phospholipids in the presence of millimolar extracellular Ca²⁺ (~1.2 mM) at neutral pH (7.4) and oligomerizes into 19- to 24-subunit transmembrane β-barrel pores with an inner diameter of 13–20 nm. (The NK cell protects its own presynaptic membrane against self-perforation via densely packed, negatively charged externalized LAMP-1 [CD107a] and high-order lipid ordering.)
• Granzymes (predominantly Granzyme B and Granzyme A): Serine proteases that enter the target cell cytosol through perforin pores (or perforin-triggered endosomolysis). Granzyme B cleaves substrates immediately after aspartate residues, directly processing and activating executioner pro-caspase-3 and pro-caspase-7 while cleaving the BH3-only protein Bid into tBid (which oligomerizes BAX/BAK on the mitochondrial outer membrane to release cytochrome c and trigger intrinsic apoptosis). Granzyme A induces caspase-independent cell death via the SET complex and single-stranded DNA nicking.

1. Death Receptor Engagement (FasL and TRAIL): Activated NK cells display surface Fas Ligand (FasL / CD178) and TRAIL (TNF-Related Apoptosis-Inducing Ligand), which trimerize Fas (CD95) and DR4/DR5 on the target cell, recruiting the FADD adaptor and activating initiator caspase-8 to drive extrinsic apoptosis. A single NK cell can detach and kill 4 to 6 target cells sequentially ("serial killing"), switching from rapid perforin/granzyme degranulation on early encounters to FasL-mediated killing once its granule stores are depleted.

Why doesn't a mother's NK cells reject a semi-allogeneic fetus that expresses paternal HLA antigens?

Extravillous trophoblast cells of the fetal placenta invade the maternal uterine decidua (where specialized decidual NK [dNK] cells constitute ~70% of leukocytes) using a selective MHC expression profile: trophoblasts lack polymorphic HLA-A and HLA-B (preventing maternal T-cell allorecognition), but express HLA-C, non-classical HLA-E (which engages inhibitory CD94/NKG2A), and HLA-G (which binds inhibitory LILRB1 and KIR2DL4 on dNK cells). Rather than lysing the trophoblast, dNK cells secrete VEGF, PlGF, and spiral-artery-remodeling factors essential for placental vascularization; however, when a mother possesses two inhibitory KIR AA haplotypes without activating KIR2DS1 and the fetus carries a paternal HLA-C2 allele, excessive dNK inhibition impairs spiral artery remodeling and predisposes to preeclampsia.

How can NK-cell-based adoptive immunotherapy (such as CAR-NK cells) avoid causing graft-versus-host disease (GvHD)?

In allogeneic T-cell transplantation, donor αβ T-cell receptors recognize recipient polymorphic MHC molecules directly as foreign, triggering potentially fatal graft-versus-host disease (GvHD) across skin, gut, and liver. Because NK cells lack T-cell receptors and are inhibited by healthy recipient tissues expressing normal self-HLA Class I (while lacking stress-induced NKG2D/NCR ligands), allogeneic off-the-shelf NK cells and chimeric antigen receptor (CAR)-NK cells selectively eliminate stressed or HLA-deficient leukemia/lymphoma cells without attacking healthy host tissues or causing GvHD.

What happens in patients with selective human Natural Killer cell deficiency (NKD)?

Patients with rare monogenic classical or functional NK cell deficiencies (caused by mutations in GATA2, MCM4, or FCGR3A [CD16]) experience severe, recurrent, and often fatal infections specifically with herpesviruses—including herpes simplex virus (HSV-1/2), varicella-zoster virus (VZV), Epstein–Barr virus (EBV), and cytomegalovirus (CMV)—as well as human papillomavirus (HPV). Because herpesviruses evolved numerous viral proteins (such as CMV US2, US3, US6, and US11) that downregulate host MHC Class I to hide from CD8⁺ T cells, NK cells via missing-self recognition are indispensable for controlling herpesviral replication before adaptive immunity matures.

1. Kiessling, R., Klein, E., & Wigzell, H. (1975). "'Natural' killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype." European Journal of Immunology, 5(2), 112–117. https://doi.org/10.1002/eji.1830050208
2. Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986). "Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy." Nature, 319(6055), 675–678. https://doi.org/10.1038/319675a0
3. Lanier, L. L. (2005). "NK cell recognition." Annual Review of Immunology, 23, 225–274. https://doi.org/10.1146/annurev.immunol.23.021704.115526
4. Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008). "Functions of natural killer cells." Nature Immunology, 9(5), 503–510. https://doi.org/10.1038/ni1582